(Q46948697)

26 December 2017

title

Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis (English)

1 reference

26 December 2017

0 references

3

1 reference

26 December 2017

Michael J. Econs

4

1 reference

26 December 2017

Michael McClung

7

1 reference

26 December 2017

Maria Luisa Brandi

10

object named as

M L Brandi

1 reference

26 December 2017

author name string

S Adami

1

1 reference

26 December 2017

J San Martin

2

1 reference

26 December 2017

L Xie

5

1 reference

26 December 2017

G P Dalsky

6

1 reference

26 December 2017

D Felsenberg

8

1 reference

26 December 2017

J P Brown

9

1 reference

26 December 2017

A Sipos

11

1 reference

26 December 2017

language of work or name

English

0 references

publication date

16 October 2007

1 reference

26 December 2017

Osteoporosis International

published in

1 reference

26 December 2017

volume

19

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

page(s)

87-94

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1007/s00198-007-0485-y

exact match

0 references

cites work

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]

1 reference

12 December 2020

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

12 December 2020

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

1 reference

12 December 2020

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

1 reference

12 December 2020

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

1 reference

12 December 2020

Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats

1 reference

12 December 2020

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

12 December 2020

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

12 December 2020

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

1 reference

12 December 2020

Assessment of fracture risk

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

1 reference

12 December 2020

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

1 reference

12 December 2020

The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation

1 reference

12 December 2020

Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis

1 reference

12 December 2020

Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

12 December 2020

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate

1 reference

12 December 2020

Epidemiology, etiology, and diagnosis of osteoporosis

1 reference

12 December 2020

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

1 reference

12 December 2020

Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment

1 reference

12 December 2020

10.1007/S00198-007-0485-Y

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017